Spectrum Pharmaceuticals, Inc.
Represented Spectrum Pharmaceuticals (NASDAQ: SPPI) in its Rule 144A offering of $120 million aggregate principal amount of its 2.75% convertible senior notes due 2018. The Convertible Notes were offered and sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Act"). Jefferies LLC and RBC Capital Markets were the underwriters. Royal Bank of Canada served as counterparty to convertible note hedge and warrant transactions in connection with the offering.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology.